PRKCD Gene Autoimmune Lymphoproliferative Syndrome Type 3 (ALPS3) Genetic Test

Executive Summary & Core Metrics

Executive Summary

Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO‑certified NGS processing and AI‑augmented variant interpretation.
Premium Logistics: VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection (daily 8 AM – 11 PM).
Clinical Guidance: Dedicated telephonic post‑test clinical counselling session with a DHA‑licensed genetic counsellor.
Insurance: Direct billing verification via WhatsApp +971 54 548 8731.

Test Overview & Methodology

The PRKCD gene (protein kinase C delta) is the master regulator of lymphocyte apoptosis and immune homeostasis. This NGS test sequences the entire coding region to identify pathogenic variants linked to Autoimmune Lymphoproliferative Syndrome Type 3 (ALPS3), a condition marked by chronic lymphadenopathy, splenomegaly, cytopenias, and heightened lymphoma risk.

Feature	Our Test (ISO‑Certified)	Alternative Lab
Methodology	NGS with full PRKCD gene coverage & copy‑number analysis	Limited hotspot panel or targeted Sanger sequencing
Turnaround Time	3‑4 Weeks (expedited options available)	6‑8 Weeks
Clinical Support	Integrated pre‑test genetic counselling & pedigree analysis	Report only
Regulatory Compliance	DHA/MOHAP norms, ISO 9001:2015, UAE PDPL	Variable

Physician Insight & Safety Protocols

“As a medical geneticist, I recognize that seeking a genetic explanation for years of unexplained autoimmune symptoms is a deeply personal journey. The PRKCD gene result—whether positive or negative—provides a biological compass, but it must be interpreted alongside your complete clinical picture and family history, never in isolation. Please use this knowledge to empower collaborative care with your specialist, not to self‑diagnose or abruptly alter treatment.”

— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403

Safety & Exclusion Notice

Medication Warning: Do not discontinue or modify prescribed immunosuppressive, corticosteroid, or any other medications without explicit instruction from your treating physician.
Exclusion Criteria: Active severe infection requiring hospitalisation, known coagulopathy if blood draw poses risk, or inability to provide informed consent (guardian must be present for minors in accordance with Federal Decree‑Law No. 4 of 2016 on Medical Liability).
Emergency Red Flags: Go to the ER immediately if you develop sudden high fever, rapid enlargement of lymph nodes/spleen, severe pallor with dizziness, or signs of acute hemolytic anemia (dark urine, jaundice).

Advisory for Post‑Result Decisions

A genetic diagnosis of ALPS3 does not replace ongoing clinical monitoring. Regular follow‑up with a rheumatologist, immunologist, or haematologist is essential. The result should guide surveillance for lymphoma and autoimmune cytopenias but not replace standard clinical care.

Patient FAQ & Clinical Guidance

1. What does the PRKCD gene test detect, and why is it important for ALPS type 3?

This NGS test identifies pathogenic mutations in the PRKCD gene that impair lymphocyte apoptosis, confirming autoimmune lymphoproliferative syndrome type 3 and guiding targeted surveillance for lymphoma and autoimmune cytopenias. The result clarifies the molecular basis of your symptoms, enables accurate genetic counselling, and helps differentiate ALPS3 from other immune dysregulation disorders.

2. How should I prepare for the test, and is a genetic counselling session mandatory?

A pre‑test genetic counselling session is mandatory to construct a detailed three‑generation pedigree chart of family members affected by PRKCD‑related ALPS, ensuring accurate risk assessment and informed consent. No special dietary restrictions or medication changes are required before sample collection. Simply book your home collection or visit our centre with your clinical records.

3. What happens after I receive my results, and how will my data be protected?

Following result delivery, a telephonic clinical guidance session connects you with a DHA‑licensed specialist to explain the findings, recommend next steps, and coordinate with your rheumatologist or immunologist—all under strict UAE Personal Data Protection Law (PDPL) ensuring genetic privacy. Your genomic data is stored on encrypted servers within the UAE and never shared without explicit consent.

4. Can the test be performed on children, and what are the consent requirements?

Yes, the test is suitable for children with clinical suspicion of ALPS3. Written informed consent must be obtained from a parent or legal guardian, in compliance with Federal Decree‑Law No. 4 of 2016 on Medical Liability. A paediatric genetic counsellor is available to explain the implications before the sample is taken.

5. Does the test screen for other genetic conditions beyond ALPS3?

No, this is a targeted single‑gene test for the PRKCD gene only. Incidental findings are not reported unless they are medically actionable and explicitly consented to during pre‑test counselling. If a broader evaluation is needed, a whole exome or genome sequencing approach may be recommended separately.

UAE Regulatory & Data Privacy Adherence

Your genetic data is protected under UAE law:

Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL): Governs the collection, processing, and storage of your genomic data. Your data remains confidential and is never shared without explicit consent.
Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields: Ensures that electronic health records and telemedicine services meet security and interoperability standards.
Federal Decree‑Law No. 4 of 2016 on Medical Liability: Establishes your right to informed consent and sets standards for medical practice, including genetic testing.

All genetic tests performed at DNA Labs UAE comply with DHA and MOHAP regulations.

Clinical & Logistical Metadata

Test Name	PRKCD Gene Autoimmune Lymphoproliferative Syndrome Type 3 (ALPS3) Genetic Test
Price (AED)	2,800 AED
Turnaround Time	3–4 Weeks (expedited options available)
Sample Type / Matrix	Peripheral whole blood (EDTA)
Methodology Used	Next‑Generation Sequencing (NGS) with full gene coverage and copy‑number analysis
ICD‑10‑CM Code	D47.29 (Other specified neoplasms of uncertain behavior of lymphoid, hematopoietic and related tissue)
LOINC Code	94400-8 (PRKCD gene mutation analysis in Blood or Tissue by NGS)
DHA Facility License & Laboratory Address	DHA License No. 1143 \| Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE \| DNA Labs UAE